{"id":76855,"date":"2020-10-07T10:00:00","date_gmt":"2020-10-07T10:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2739779"},"modified":"2020-10-07T10:00:00","modified_gmt":"2020-10-07T10:00:00","slug":"global-hemostasis-products-market-set-for-rapid-growth-to-reach-around-usd-5-30-billion-by-2021","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/10\/07\/global-hemostasis-products-market-set-for-rapid-growth-to-reach-around-usd-5-30-billion-by-2021\/","title":{"rendered":"Global Hemostasis Products Market Set for Rapid Growth, to Reach Around USD 5.30 Billion By 2021"},"content":{"rendered":"

Some of the major companies in the global hemostasis products market are Medtronic plc, Pfizer, Inc., Johnson & Johnson, Abbott Laboratories, HemCon Medical Technologies, Inc., Integra LifeSciences Corporation, CSL Behring LLC, Grifols, S.A., Baxter International, Inc., and C. R. Bard, Inc. These players are likely to drive the global hemostasis products market in the years to come.<\/p>\n

According to the analysts at Zion Market Research, theglobal hemostasis products market<\/a>was capitalized at almost USD 5.30 Billion in 2015 and is likely to cross almost USD 6.70 Billion by 2021, developing at a CAGR of almost 4.0% from 2016 to 2021.<\/p>\n

Get Free Sample Of Report –<\/strong> https:\/\/www.zionmarketresearch.com\/sample\/hemostasis-products-market<\/a><\/p>\n

Furthermore, rising prevalence of chronic conditions and rapid increment in aged population base are other factors driving the global hemostasis products market. As per the CDC statistics, over 45% of the population in the U.S suffers from minimum one chronic disease that needs important care, boosting the hemostasis products market. On the other hand, slow acceptance of enhanced hemostasis instruments in up-and-coming economies and the high price of machines might hinder the growth of the hemostasis products market in the near future.<\/p>\n

In addition to this, increasing job opportunities also seems to give a helping hand in powering the development of the global hemostasis products market. Various new product launches by market players is also considered to be one of the major reasons that is responsible for the development of the hemostasis products market. For instance, in December 2017, Starch Medical Inc. expanded its product lineup with the roll out of SuperClot Hemostat in Europe. Starch is a privately held marketer and manufacturer of polysaccharide-supported hemostasis products for employment in managing bleeding in trauma and surgery applications.<\/p>\n

Increasing Numbers Of Complex Surgeries And Trauma Cases To Favor The Hemostasis Products Market In North America<\/strong><\/p>\n

North America ruled the hemostasis products market and added up for more than 35% share in the revenues by the global hemostasis products market. The area is likely to see development in hemostasis products market at a considerable speed in the near future. The increasing numbers of complex surgeries and trauma cases, high investment is R&D, and the growth of geriatric population are also boosting the hemostasis products market in North America.<\/p>\n

The global hemostasis products market is segmented as follows:<\/strong><\/p>\n

By Product<\/strong><\/p>\n